P2Y12 is a chemoreceptor for ADP (adenosine diphosphate) belonging to the Gi class of a group of G protein-coupled (GPCR) purinergic receptors. The P2Y12 receptor is required during platelet aggregation and is a target during the treatment of clotting disorders and thromboembolisms. Ticlopidine, prasugrel, clopidogrel, cangrelor and ticlopidine are a few P2Y12 receptor blocker group of drugs. These drugs are an antiplatelet drugs, which means these are medicines that inhibit platelets from adhering with each other and forming a clot, which eventually leads to a heart attack or stroke.
The U.S. P2Y12 inhibitors market is expected to be valued at US$ 215.7 Mn in 2021, and is anticipated to exhibit a CAGR of 3.8% during the forecast period.
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/4983
Impact of COVID-19:
Lockdowns have been imposed in many countries around the world due to COVID-19 has infection impacted and also affected the financial status of all sectors. Healthcare sector has been majorly impacted by this pandemic as there has been a shortage of manpower, resources and consumables. The pandemic has negatively impacted the manufacturing, production and supply of pharmaceutical products of several companies. This lockdown also led to closure of various industrial establishments and disturbances in the supply chain of products. Manufacturing activities in countries like the U.K., Italy, the U.S., India and Spain have been disrupted due to the strict lockdowns in these nations. Supply chain and manufacturing activities in India, Italy, Spain, the U.K., and the U.S. have been disrupted due to lockdowns implemented by governments in the past few months, while countries such as Brazil, France, Russia, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drug products. Many countries like France, Saudi Arabia, Egypt, Russia, Brazil, UAE and many others are facing challenges in transportation of drug products due to disruptions in the transportation system. Shortages of resources in the healthcare industry ha negatively impacted the economy of the healthcare sector. COVID-19 has impacted the U.S. P2Y12 inhibitors market and the economy globally.
Increasing prevalence of cardiovascular diseases is anticipated to boost the growth of the U.S. P2Y12 Inhibitors market during the forecast period. For instance, the Centers for Disease Control and Prevention, published their data in September 2021, stating that heart diseases are the major cause of death in adults in the U.S. Every year around 659,000 people in the die from heart diseases in the United States of America.
Furthermore, key players in the market are focusing on product approvals from the regulatory authorities, which is estimated to boost the growth of the U.S. P2Y12 Inhibitors market during the forecast period. For instance, Brilinta developed by AstraZeneca, has gained approval in the United States of America. The drug is used for reducing the risk of heart attack in patients suffering from coronary artery disease
Request Here PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/4983
Potential side effects of various drugs is a major restraining factor and it is expected to hamper the growth of the U.S. P2Y12 inhibitors market during the forecast period. For instance, P2Y12 inhibitors can have side effects like nausea, diarrhea, stomach pain, itching and skin rash. Ticlopidine can cause an immune disorder leading to low white blood cell count and destroying of paltelets. Ticagrelor can also lead to dyspnea or shortness of breath.
Key players active in the U.S. P2Y12 inhibitors market are Biocon, Mylan N.V., Cipla, Bristol-Myers Squibb, Lupin, Dr Reddy’s Laboratories, CHIESI USA, Inc, Teva Pharmaceuticals USA, Inc, Panacea Biotec, AstraZeneca, Eli Lilly and Company and Genentech.
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 U.S. P2Y12 Inhibitors Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: U.S. P2Y12 Inhibitors Industry Impact
Chapter 2 Global U.S. P2Y12 Inhibitors Competition by Types, Applications, and Top Regions and Countries
2.1 Global U.S. P2Y12 Inhibitors (Volume and Value) by Type
2.3 Global U.S. P2Y12 Inhibitors (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global U.S. P2Y12 Inhibitors Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America U.S. P2Y12 Inhibitors Market Analysis
Chapter 6 East Asia U.S. P2Y12 Inhibitors Market Analysis
Chapter 7 Europe U.S. P2Y12 Inhibitors Market Analysis
Chapter 8 South Asia U.S. P2Y12 Inhibitors Market Analysis
Chapter 9 Southeast Asia U.S. P2Y12 Inhibitors Market Analysis
Chapter 10 Middle East U.S. P2Y12 Inhibitors Market Analysis
Chapter 11 Africa U.S. P2Y12 Inhibitors Market Analysis
Chapter 12 Oceania U.S. P2Y12 Inhibitors Market Analysis
Chapter 13 South America U.S. P2Y12 Inhibitors Market Analysis
Chapter 14 Company Profiles and Key Figures in U.S. P2Y12 Inhibitors Business
Chapter 15 Global U.S. P2Y12 Inhibitors Market Forecast (2022-2028)
Chapter 16 Conclusions
Direct Buy This Premium Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4983
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027